MedTrace Logo

An Open-label Study of AZD0120 in Adults With Multiple Sclerosis

NCT07224373 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2026-05-22

No results posted yet for this study

Summary

This trial is a Phase 1b, open-label, multi-center, clinical study of AZD0120, a BCMA/CD19 dual targeting CAR+ T-cell therapy, to evaluate the safety and tolerability in adult participants with Multiple Sclerosis.

Conditions

Interventions

BIOLOGICAL

AZD0120 - Regimen 1

Regimen 1, infusion of AZD0120

BIOLOGICAL

AZD0120 - Regimen 2

Regimen 2, infusion of AZD0120

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-09
Primary Completion
2028-12-07
Completion
2028-12-07
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Canada
  • Germany
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07224373 on ClinicalTrials.gov